{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:08:14Z","timestamp":1790525294243,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":5054,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1017\/s1041610210001146","type":"journal-article","created":{"date-parts":[[2010,7,30]],"date-time":"2010-07-30T09:15:51Z","timestamp":1280481351000},"page":"238-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prescribing trends in cognition enhancing drugs in Australia"],"prefix":"10.1016","volume":"23","author":[{"given":"Samantha A.","family":"Hollingworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1017\/S1041610210001146_bb0010","series-title":"Population by Age and Sex, Australian States and Territories","author":"Australian Bureau of Statistics","year":"2007"},{"key":"10.1017\/S1041610210001146_bb0015","series-title":"Pharmaceutical Benefits Schedule","author":"Australian Government Department of Health and Ageing","year":"2006"},{"key":"10.1017\/S1041610210001146_bb0020","series-title":"Australian Statistics on Medicines, 2006","author":"Australian Government Department of Health and Ageing","year":"2008"},{"key":"10.1017\/S1041610210001146_bb0025","series-title":"Dementia in Australia: National Data Analysis and Development","author":"Australian Institute of Health and Welfare","year":"2007"},{"key":"10.1017\/S1041610210001146_bb0030","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.1017\/S1041610210001146_bb0035","doi-asserted-by":"crossref","unstructured":"Birks J. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews, CD005593.","DOI":"10.1002\/14651858.CD005593"},{"key":"10.1017\/S1041610210001146_bb0040","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/bmj.299.6712.1375","article-title":"Effect of a training programme to reduce stress in carers of patients with dementia","volume":"299","author":"Brodaty","year":"1989","journal-title":"BMJ"},{"key":"10.1017\/S1041610210001146_bb0045","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/j.1440-1614.2005.01712.x","article-title":"Dementia: new projections and time for an updated response","volume":"39","author":"Brodaty","year":"2005","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1017\/S1041610210001146_bb0050","series-title":"Australia to 2050: Future Challenges","author":"Commonwealth of Australia","year":"2010"},{"key":"10.1017\/S1041610210001146_bb0055","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial","volume":"363","author":"Courtney","year":"2004","journal-title":"Lancet"},{"key":"10.1017\/S1041610210001146_bb0060","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1532-5415.2007.01377.x","article-title":"A population-based study of cholinesterase inhibitor use for dementia","volume":"55","author":"Herrmann","year":"2007","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1017\/S1041610210001146_bb0065","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa066583","article-title":"Donepezil for the treatment of agitation in Alzheimer's disease","volume":"357","author":"Howard","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1017\/S1041610210001146_bb0070","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1080\/j.1440-1614.2005.01713.x","article-title":"Projections of future numbers of dementia cases in Australia with and without prevention","volume":"39","author":"Jorm","year":"2005","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1017\/S1041610210001146_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10010","article-title":"The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease","volume":"10","author":"Loveman","year":"2006","journal-title":"Health Technology Assessment"},{"key":"10.1017\/S1041610210001146_bb0080","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1176\/appi.ajp.157.5.708","article-title":"Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging","volume":"157","author":"Lyketsos","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610210001146_bb0085","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/00019442-200510000-00009","article-title":"Mental health-related drug utilization among older adults: prevalence, trends, and costs","volume":"13","author":"Mamdani","year":"2005","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610210001146_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/gps.1493","article-title":"Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs","volume":"21","author":"Oude Voshaar","year":"2006","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610210001146_bb0095","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/pds.1613","article-title":"Prevalence of cholinesterase inhibitors in subjects with dementia in Europe","volume":"17","author":"Pariente","year":"2008","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1017\/S1041610210001146_bb0100","first-page":"e1000157","article-title":"Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study","volume":"6","author":"Park-Wyllie","year":"2009","journal-title":"Public Library of Science (PLoS) Medicine"},{"key":"10.1017\/S1041610210001146_bb0105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/pds.1739","article-title":"Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors","volume":"18","author":"Robinson","year":"2009","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1017\/S1041610210001146_bb0110","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1017\/S1041610209990354","article-title":"Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine","volume":"21","author":"Rodda","year":"2009","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610210001146_bb0115","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1212\/01.wnl.0000320508.11013.4f","article-title":"High prevalence of dementia and cognitive impairment in indigenous Australians","volume":"71","author":"Smith","year":"2008","journal-title":"Neurology"},{"key":"10.1017\/S1041610210001146_bb0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/gps.1402","article-title":"A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease","volume":"21","author":"Takeda","year":"2006","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610210001146_bb0125","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4088\/JCP.v69n0302","article-title":"Memantine for agitation\/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies","volume":"69","author":"Wilcock","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610210001146_bb0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000102568","article-title":"Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomized clinical trials","volume":"24","author":"Winblad","year":"2007","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1017\/S1041610210001146_bb0135","unstructured":"World Health Organization (2008). ATC\/DDD Index. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. Available at http:\/\/www.whocc.no\/atcddd\/."}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224028540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224028540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1041610210001146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T09:25:49Z","timestamp":1736414749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1041610224028540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S1041610224028540"],"URL":"https:\/\/doi.org\/10.1017\/s1041610210001146","relation":{},"ISSN":["1041-6102"],"issn-type":[{"value":"1041-6102","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescribing trends in cognition enhancing drugs in Australia","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1017\/S1041610210001146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 International Psychogeriatric Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}